TRAW Price / Book | Traws Pharma, Inc.

Traws Pharma, Inc. Price/Book Ratio

The price-to-book (P/B) ratio compares what the stock market says a company is worth with what the company's own books say it is worth. It is market capitalization divided by shareholder equity, the book value left after subtracting liabilities from assets, and the table shows both amounts. A ratio of 1.0 means market value equals book value; a higher ratio means investors value the company above its net assets, often for brands, software or expected growth the books do not record. A negative ratio means equity is negative. Each point uses the filed share count and the last closing price on or before the equity's reporting date, never today's price.

Traws Pharma, Inc. price/book ratio for the quarter ending 2026-06-30 was 7.43, a 490.39% increase year-over-year.
Traws Pharma, Inc. price/book ratio for the quarter ending 2026-03-31 was -3.64, a 286.87% decline year-over-year.
Traws Pharma, Inc. price/book ratio for the quarter ending 2025-12-31 was -16, a change of -14.98 year-over-year.
Traws Pharma, Inc. price/book ratio for the quarter ending 2025-09-30 was 2.95, a change of 11.7 year-over-year.
Traws Pharma, Inc. price/book ratio for fiscal 2026 was 7.43.
Traws Pharma, Inc. price/book ratio for fiscal 2025 was -16, a change of -14.98 from fiscal 2024.
Traws Pharma, Inc. price/book ratio for fiscal 2024 was -1.02, a 169.43% decline from fiscal 2023.
Traws Pharma, Inc. price/book ratio for fiscal 2023 was 1.48, a 87.71% decline from fiscal 2022.

Available history: 2013-12-31 to 2026-06-30
Data captured: 2026-06-30

Historical Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	7.43	$12.56M	$1.69M
2026-03-31	-3.64	$19.31M	-$5.31M
2025-12-31	-16	$10.07M	-$629,000.00
2025-09-30	2.95	$13.41M	$4.55M
2025-06-30	1.26	$10.39M	$8.26M
2025-03-31	1.95	$11.67M	$6M
2024-12-31	-1.02	$32.42M	-$31.63M
2024-09-30	-8.75	$17.79M	-$2.03M
2024-06-30	-2.7	$284.7M	-$105.52M
2024-03-31	88.52	$532.42M	$6.02M
2023-12-31	1.48	$15.75M	$10.67M
2023-09-30	25.68	$372.81M	$14.52M
2023-06-30	32.75	$618.84M	$18.9M
2023-03-31	16.73	$382.69M	$22.88M
2022-12-31	12.01	$340.05M	$28.31M
2022-09-30	13.8	$460.37M	$33.37M
2022-06-30	17.92	$689.55M	$38.48M
2022-03-31	22.73	$961.2M	$42.29M
2021-12-31	28.88	$1.33B	$46.12M
2021-09-30	40.27	$2B	$49.67M
2021-06-30	82.87	$2.73B	$32.99M
2021-03-31	2,388.98	$88.76B	$37.15M
2020-12-31	353.82	$2.18B	$6.18M
2020-09-30	1,586.37	$19.38B	$12.22M
2020-06-30	2,381.53	$37.23B	$15.63M
2020-03-31	882.25	$18.83B	$21.35M
2019-12-31	1,368.7	$15.84B	$11.57M
2019-09-30	-432.53	$2.61B	-$6.04M
2019-06-30	-1,410.23	$6.41B	-$4.55M
2019-03-31	-4,749.39	$7.3B	-$1.54M
2018-12-31	833.44	$4.49B	$5.39M
2018-09-30	1,438.15	$15.62B	$10.86M
2018-06-30	12,032.77	$191.5B	$15.92M
2018-03-31	-13,351.07	$91.79B	-$6.88M
2017-12-31	-557.85	$6.06B	-$10.86M
2017-09-30	-15,589.98	$94.76B	-$6.08M
2017-06-30	270,795.57	$119.69B	$442,000.00
2017-03-31	-42,719.46	$115.81B	-$2.71M
2016-12-31	16,835.46	$86.32B	$5.13M
2016-09-30	10,061.38	$100.76B	$10.02M
2016-06-30	43,529.19	$89.1B	$2.05M
2016-03-31	131,098.22	$893.96B	$6.82M
2015-12-31	12,685.11	$137.51B	$10.84M
2015-09-30	431,592.23	$1.81T	$4.2M
2015-06-30	633,602.2	$2.9T	$4.58M
2015-03-31	233,354.73	$2.94T	$12.61M
2014-12-31	170,029.78	$4.02T	$23.62M
2014-09-30	147,121.96	$5.25T	$35.66M
2014-06-30	135,260.01	$6.62T	$48.94M
2014-03-31	119,895.72	$7.72T	$64.36M
2013-12-31	171,355.09	$13.86T	$80.9M

Annual Price/Book Ratio

Date	Price/Book Ratio	Market capitalization	Shareholder equity
2026-06-30	7.43	$12.56M	$1.69M
2025-12-31	-16	$10.07M	-$629,000.00
2024-12-31	-1.02	$32.42M	-$31.63M
2023-12-31	1.48	$15.75M	$10.67M
2022-12-31	12.01	$340.05M	$28.31M
2021-12-31	28.88	$1.33B	$46.12M
2020-12-31	353.82	$2.18B	$6.18M
2019-12-31	1,368.7	$15.84B	$11.57M
2018-12-31	833.44	$4.49B	$5.39M
2017-12-31	-557.85	$6.06B	-$10.86M
2016-12-31	16,835.46	$86.32B	$5.13M
2015-12-31	12,685.11	$137.51B	$10.84M
2014-12-31	170,029.78	$4.02T	$23.62M
2013-12-31	171,355.09	$13.86T	$80.9M

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Alzamend Neuro, Inc. (ALZN)	United States	$0.009B
Imunon, Inc. (IMNN)	United States	$0.008B	-0.56
SOLIGENIX, INC. (SNGX)	United States	$0.008B
FibroBiologics, Inc. (FBLG)	United States	$0.009B	-0.27
EXICURE, INC. (XCUR)	United States	$0.008B	-1.54
Ensysce Biosciences, Inc. (ENSC)	United States	$0.008B	-0.37
InMed Pharmaceuticals Inc. (INM)		$0.008B	-0.65
Aprea Therapeutics, Inc. (APRE)	United States	$0.010B	-0.78
Apimeds Pharmaceuticals US, Inc. (APUS)	United States	$0.008B
CNS Pharmaceuticals, Inc. (CNSP)	United States	$0.007B